Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas.

ABSTRACT:

Purpose

Immunotherapy has been demonstrably effective against multiple cancers, yet tumor escape is common. It remains unclear how brain tumors escape immunotherapy and how to overcome this immune escape.

Experimental design

We studied KR158B-luc glioma-bearing mice during treatment with adoptive cellular therapy (ACT) with polyclonal tumor-specific T cells. We tested the immunogenicity of primary and escaped tumors using T-cell restimulation assays. We used flow cytometry and RNA profiling of whole tumors to further define escape mechanisms. To treat immune-escaped tumors, we generated escape variant-specific T cells through the use of escape variant total tumor RNA and administered these cells as ACT. In addition, programmed cell death protein-1 (PD-1) checkpoint blockade

SUBMITTER: Wildes TJ 

PROVIDER: S-EPMC9371689 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature